Last reviewed · How we verify
NCT04984395: IDT
Improving Diagnosis and Treatment of Metastatic Advanced Prostate Cancer
trial testing Post-treatment CT-guided bone marrow biopsy in Advanced Prostate Carcinoma in 50 participants. Status unknown.
31 May 2024
Quick facts
| Lead sponsor | Royal Marsden NHS Foundation Trust |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 30 July 2021 |
| Primary completion | 31 May 2024 |
| Estimated completion | 31 May 2024 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Post-treatment CT-guided bone marrow biopsy
Conditions studied
- Advanced Prostate Carcinoma — all drugs for Advanced Prostate Carcinoma →
Sponsor
Royal Marsden NHS Foundation Trust
Who can join
18 and older, male only, with Advanced Prostate Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to provide clinical evidence to determine if Whole Body Magnetic Resonance Imaging (WBMRI) with a novel technique called diffusion-weighted imaging (DWI) can improve current treatment for APC patients, allowing for early identification of disease progression or treatment response, hence facilitating clinical decision-making and leading to improvement in patient care. The IDT study includes two retrospective analyses and a single centre prospective observational study for APC patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04984395
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Prostate Carcinoma
Currently open trials in the same condition.
- NCT05869682 — Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Underg · Phase 2 · recruiting
- NCT05969860 — At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer · Phase 2 · recruiting
- NCT05396872 — Patient Decision-making About Precision Oncology in Veterans With Advanced Prostate Cancer · NA · recruiting
- NCT04514484 — Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and · Phase 1 · active not recruiting
- NCT04346225 — Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer · Phase 2 · recruiting
Other Royal Marsden NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07407686 — Improving Engagement From Underserved Communities With Prostate Cancer Genetics Services · not yet recruiting
- NCT07243834 — Assessing a Digital Exercise Intervention for Health Outcomes and Engagement in Regular Exercise · NA · recruiting
- NCT06605833 — CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma · enrolling by invitation
- NCT07008742 — Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Canc · recruiting
- NCT06560905 — Preoperative Planning With PSMA-PET in Melanoma Surgery Trial · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04984395 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Royal Marsden NHS Foundation Trust
- Last refreshed: 30 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04984395.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing